The Global Leptospirosis Market Size is valued at 467.07 million in 2022 and is predicted to reach 813.73 million by the year 2031 at a 6.47% CAGR during the forecast period for 2023-2031.
Leptospirosis is a bacterial infection caused by the bacterium Leptospira. The bacterium is present in the kidneys of several mammals. When contaminated animal poo material is present in the soil and water, it spreads to humans through skin breaks such as cuts, open sores, or dry places. It spreads through the nose, mouth, and genitals, but contracting it from another person is challenging; however, it can be transmitted via physical contact or nursing.
The global leptospirosis market was studied and is predicted to expand significantly throughout the forecast period. Leptospirosis is a condition caused by the bacteria Leptospira. The bacteria are common in soil and water, and contact with contaminated urine or tissue can spread to humans and animals.
Conversely, the high cost of treatment will hamper the market's growth rate. In emerging economies, a lack of experienced personnel and a lack of healthcare infrastructure would provide challenges to the leptospirosis industry. Furthermore, there needs to be more clinical suspicion and limitations to diagnostic capacity and public awareness.
Recent Developments:
- In July 2022, Mylab Discovery Solutions introduced the 'PathoDetect Extended Monsoon Fever Panel,' a comprehensive multiplex RT PCR test kit for all monsoon diseases, including malaria, chikungunya, dengue, zika, Leptospirosis, and salmonellosis bacterial species, and Leishmaniasis parasites.
- In April 2022, As the monsoon season raises the risk of Leptospirosis, the health ministry of Kerela state in India initiated a campaign, Mrityunjayam, to raise awareness about the disease.
Competitive Landscape:
Some of the Leptospirosis market players are:
- USAntibiotics
- Reddy's Laboratories Ltd.
- Century Pharmaceuticals Ltd.
- Mayne Pharma Group Limited
- Sun Pharmaceutical Industries, Inc.
- Ralington Pharma
- Hoffmann-La Roche Ltd
- Pfizer Inc.
- Sandoz International GmbH
- ISKON REMEDIES & GMT
- Haustus Biotech Pvt. Ltd.
- Aden Healthcare
Market Segmentation:
The Leptospirosis market is segmented based on drug, diagnosis, route of administration and distribution channel. The drug market is segmented into Amoxicillin, azithromycin, cefixime, and doxycycline. The other drug segment includes ceftriaxone and penicillin. The market is segmented by diagnosis into complete blood count (CBC), creatine kinase, liver enzymes, and urinalysis. The other drug segments include lumbar puncture, and microscopic agglutination tests, among others. Route of administration segment includes oral, parenteral, and intravenous. Distribution channel segment includes hospital pharmacies, retail pharmacies, and online pharmacies.
Based On The Drug, The Amoxicillin Segment Is A Major Contributor To Leptospirosis
The amoxicillin category will hold a major share of the global Leptospirosis market 2021. This is attributed to the growth in the usage of Amoxicillin for the treatment of Leptospirosis based on guidelines provided by government agencies. Penicillin antibiotic amoxicillin. It treats bacterial illnesses like lung infections (like pneumonia) and dental abscesses. It can also treat stomach ulcers in conjunction with other antibiotics and medications.
The Hospital Pharmacies Segment Exhibited Growth At A Rapid Rate
The hospital pharmacies segment is projected to grow rapidly in the global Leptospirosis market. In severe cases, such as jaundice, renal failure, or pulmonary hemorrhage, Leptospirosis necessitates hospitalization and extensive treatment.
The North America Leptospirosis Market Holds A Significant Revenue Share In The Region
The North America Leptospirosis market is expected to record the highest market share in revenue shortly. Due to increased leptospirosis epidemics, increased awareness of bacterial illnesses, the existence of medication manufacturers, and increased natural catastrophes resulting in bacterial pollution and zoonosis. For example, according to statistics supplied by the Centres for Disease Control and Prevention in 2022, the United States suffered leptospirosis epidemics in 2021 due to floods in Hawaii, Florida, and Puerto Rico.
Furthermore, according to a study titled "Leptospirosis in the Elderly: the Role of Age as a Predictor of Poor Outcomes in Hospitalised Patients," publicized in the National Library of Medicine in 2020, the hospitalization rate for Leptospirosis in the United States was higher for elderly patients when compared to younger individuals, particularly those under the age of 20.
Leptospirosis Market Report Scope:
|
Report Attribute |
Specifications |
|
Market size value in 2022 |
USD 467.07 Mn |
|
Revenue forecast in 2031 |
USD 813.73 Mn |
|
Growth rate CAGR |
CAGR of 6.47 % from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Billion, and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Drug, Diagnosis, Route Of Administration And Distribution Channel |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
USAntibiotics, Dr. Reddy's Laboratories Ltd., Century Pharmaceuticals Ltd., Mayne Pharma Group Limited, Sun Pharmaceutical Industries, Inc., Arlington Pharma, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sandoz International GmbH, ISKON REMEDIES & GMT, Haustus Biotech Pvt. Ltd., and Aden Healthcare. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
